Bessemer Group Inc. Has $1.04 Million Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Bessemer Group Inc. lessened its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 70.5% in the first quarter, according to its most recent filing with the SEC. The fund owned 6,935 shares of the medical research company's stock after selling 16,538 shares during the period. Bessemer Group Inc.'s holdings in Charles River Laboratories International were worth $1,044,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of CRL. D1 Capital Partners L.P. purchased a new stake in Charles River Laboratories International in the 4th quarter worth about $172,752,000. Assenagon Asset Management S.A. increased its holdings in shares of Charles River Laboratories International by 1,721.1% in the 1st quarter. Assenagon Asset Management S.A. now owns 570,097 shares of the medical research company's stock valued at $85,811,000 after purchasing an additional 538,792 shares during the period. Norges Bank purchased a new stake in shares of Charles River Laboratories International in the fourth quarter worth approximately $98,886,000. Wellington Management Group LLP boosted its holdings in shares of Charles River Laboratories International by 9.0% during the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock worth $752,508,000 after purchasing an additional 335,658 shares during the period. Finally, Nomura Holdings Inc. purchased a new position in Charles River Laboratories International during the fourth quarter valued at approximately $56,820,000. 98.91% of the stock is owned by institutional investors.

Insider Activity

In related news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the sale, the executive vice president owned 19,513 shares of the company's stock, valued at $2,837,385.33. The trade was a 2.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Stock Performance

CRL traded down $0.37 during trading on Thursday, reaching $157.12. 247,068 shares of the company's stock were exchanged, compared to its average volume of 1,023,708. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $254.15. The company has a market capitalization of $7.72 billion, a P/E ratio of -241.72, a PEG ratio of 5.23 and a beta of 1.49. The company has a quick ratio of 1.16, a current ratio of 1.43 and a debt-to-equity ratio of 0.78. The business has a 50 day moving average price of $139.03 and a 200 day moving average price of $153.16.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. The business had revenue of $984.17 million for the quarter, compared to analysts' expectations of $942.34 million. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The firm's revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.27 earnings per share. As a group, analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on CRL. Wall Street Zen cut shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Friday, June 27th. TD Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price on the stock in a research report on Wednesday, May 14th. Robert W. Baird lifted their price target on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research report on Thursday, May 8th. Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. Finally, Barclays boosted their target price on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 8th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $171.85.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).